Wednesday, 26th of October, Washington DC - Insilico Medicine, Inc. announced that it will present its most recent advances in applying the deep learning techniques to biomarker development and drug discovery at the GPU Technology Conference Washington DC (GTC DC). Dr. Qingsong Zhu, Chief Operating Officer at Insilico Medicine, will give a presentation on October 27th in the "Heathcare" track.
The presentation titled "Deep Learning Pipelines for Drug Discovery" will cover Insilico Medicine's most recent progress of the applications of deep learning techniques on large transcriptional response data and creating multi-modal biomarkers and predictors of therapeutic use of the drugs for high throughput screening.
Deep learning is rapidly advancing in many areas of science and technology, such as imaging, texting, voice recognition, robotics, and autonomous driving. The adoption of deep learning in biomedicine, especially drug discovery, has been relatively slow. With the development of high throughput technologies, such as microarray and next generation sequencing (NGS), high dimensional -omics data are massively accumulating, which has become a tremendous challenge to the scientists. Deep learning is a series of algorithms developed for efficient abstractions from these heterogeneous and high dimensional data.
"GTC is one of the best conferences on deep learning to bridge academia and industry. I am very thankful to the organizers for having the opportunity to present our research. Insilico Medicine is clearly one of the leaders in the field. We are applying deep learning technologies and our Pathway Activation Strength Analysis algorithms in drug discovery. The algorithms allow us to solve complex problems ranging from biomarker development to precision drug discovery," said Qingsong Zhu, Ph.D., the COO at Insilico Medicine.
GPU Technology Conference (GTC) is the largest and most important event of the year for GPU developers. GTC and the global GTC event series offer valuable training and a showcase of the most vital work in the computing industry today - including artificial intelligence and deep learning, virtual reality, and self-driving cars. Website: http://dc.
About Insilico Medicine
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https:/